NOVO NORDISKDRNNOVO NORDISKDRNNOVO NORDISKDRN

NOVO NORDISKDRN

No trades
See on Supercharts

Key facts today


Novo Nordisk's market share in the anti-obesity sector has dropped due to production issues and Wegovy shortages, allowing competitors like Eli Lilly to gain ground with better treatments.
Novo Nordisk (NOVO_B) saw a decline of 1.8% in trading, aligning with the overall downward trend of European equities traded in the US, particularly among American depositary receipts.
Analyze the impactAnalyze the impact
Market capitalization
‪1.77 T‬BRL
19.449BRL
‪86.65 B‬BRL
‪249.17 B‬BRL
‪3.16 B‬
Beta (1Y)
−0.45

About NOVO NORDISK B A/S


CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Founded
1931
ISIN
BRN1VOBDR005
FIGI
BBG00XX9KCX6
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
NOVO NO.F.NL 25/37 MTN
Yield to maturity
3.64%
Maturity date
May 27, 2037
N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.35%
Maturity date
May 21, 2034
N
XS300255353
NOVO NO.F.NL 25/33 MTN
Yield to maturity
3.22%
Maturity date
May 27, 2033
N
XS300255329
NOVO NO.F.NL 25/30 MTN
Yield to maturity
2.94%
Maturity date
Aug 27, 2030
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.92%
Maturity date
Jan 21, 2031
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.82%
Maturity date
Mar 31, 2030
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.59%
Maturity date
Jan 21, 2029
N
XS300255299
NOVO NO.F.NL 25/28 MTN
Yield to maturity
2.59%
Maturity date
May 27, 2028
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.58%
Maturity date
Jun 4, 2028
N
XS300255213
NOVO NO.F.NL 25/27 FLRMTN
Yield to maturity
2.48%
Maturity date
May 27, 2027
N
XS282044994
NOVO NO.F.NL 24/26 MTN
Yield to maturity
2.38%
Maturity date
May 21, 2026

See all N1VO34 bonds 


Check out other big names from the same industry as N1VO34.